Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $62.4 million.

  • Prestige Consumer Healthcare's Cash & Equivalents rose 2260.29% to $62.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $62.4 million, marking a year-over-year increase of 2260.29%. This contributed to the annual value of $97.9 million for FY2025, which is 11064.37% up from last year.
  • Prestige Consumer Healthcare's Cash & Equivalents amounted to $62.4 million in Q4 2025, which was up 2260.29% from $119.1 million recorded in Q3 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's Cash & Equivalents peaked at $163.6 million during Q2 2021, and registered a low of $21.0 million during Q4 2021.
  • In the last 5 years, Prestige Consumer Healthcare's Cash & Equivalents had a median value of $53.1 million in 2023 and averaged $64.5 million.
  • Examining YoY changes over the last 5 years, Prestige Consumer Healthcare's Cash & Equivalents showed a top increase of 31087.64% in 2022 and a maximum decrease of 7807.84% in 2022.
  • Prestige Consumer Healthcare's Cash & Equivalents (Quarter) stood at $21.0 million in 2021, then soared by 310.88% to $86.4 million in 2022, then decreased by 26.34% to $63.6 million in 2023, then decreased by 20.03% to $50.9 million in 2024, then grew by 22.6% to $62.4 million in 2025.
  • Its Cash & Equivalents was $62.4 million in Q4 2025, compared to $119.1 million in Q3 2025 and $139.5 million in Q2 2025.